These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 18175100)

  • 1. The effect of altered physiological states on intravenous anesthetics.
    Henthorn TK
    Handb Exp Pharmacol; 2008; (182):363-77. PubMed ID: 18175100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Special aspects of pharmacokinetics of inhalation anesthesia.
    Hendrickx JF; De Wolf A
    Handb Exp Pharmacol; 2008; (182):159-86. PubMed ID: 18175091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early drug distribution: a generally neglected aspect of pharmacokinetics of particular relevance to intravenously administered anesthetic agents.
    Henthorn TK; Krejcie TC; Avram MJ
    Clin Pharmacol Ther; 2008 Jul; 84(1):18-22. PubMed ID: 18563069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mixed-effects modeling of the influence of midazolam on propofol pharmacokinetics.
    Vuyk J; Lichtenbelt BJ; Olofsen E; van Kleef JW; Dahan A
    Anesth Analg; 2009 May; 108(5):1522-30. PubMed ID: 19372331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contributions of PK/PD modeling to intravenous anesthesia.
    Minto CF; Schnider TW
    Clin Pharmacol Ther; 2008 Jul; 84(1):27-38. PubMed ID: 18463625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics, efficacy, and tolerability of fentanyl following intranasal versus intravenous administration in adults undergoing third-molar extraction: a randomized, double-blind, double-dummy, two-way, crossover study.
    Christrup LL; Foster D; Popper LD; Troen T; Upton R
    Clin Ther; 2008 Mar; 30(3):469-81. PubMed ID: 18405786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and pharmacodynamics of intravenously administered anesthetic drugs: concepts and lessons for drug development.
    Kern SE; Stanski DR
    Clin Pharmacol Ther; 2008 Jul; 84(1):153-7. PubMed ID: 18463623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physiologically based pharmacokinetics (PBPK).
    Espié P; Tytgat D; Sargentini-Maier ML; Poggesi I; Watelet JB
    Drug Metab Rev; 2009; 41(3):391-407. PubMed ID: 19601719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of general anesthesia on whole body and regional pharmacokinetics of local anesthetics at toxic doses.
    Copeland SE; Ladd LA; Gu XQ; Mather LE
    Anesth Analg; 2008 May; 106(5):1440-9, table of contents. PubMed ID: 18420858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Chronomedicine: its achievements and objectives].
    Komarov FI; Rapoport SI
    Ter Arkh; 1988; 60(8):12-7. PubMed ID: 3227477
    [No Abstract]   [Full Text] [Related]  

  • 11. The pharmacokinetics and pharmacodynamics of alfaxalone in cats after single and multiple intravenous administration of Alfaxan at clinical and supraclinical doses.
    Whittem T; Pasloske KS; Heit MC; Ranasinghe MG
    J Vet Pharmacol Ther; 2008 Dec; 31(6):571-9. PubMed ID: 19000281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic-pharmacodynamic modeling in anesthesia, intensive care and pain medicine.
    Sadean MR; Glass PS
    Curr Opin Anaesthesiol; 2009 Aug; 22(4):463-8. PubMed ID: 19412091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetics of sevoflurane in conjunction with the AnaConDa: toward target-controlled infusion of volatiles into the breathing system.
    Enlund M; Kietzmann D; Bouillon T; Züchner K; Meineke I
    Acta Anaesthesiol Scand; 2008 Apr; 52(4):553-60. PubMed ID: 18339161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aging issues in drug disposition and efficacy.
    Sitar DS
    Proc West Pharmacol Soc; 2007; 50():16-20. PubMed ID: 18605223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults.
    Menon-Andersen D; Mondick JT; Jayaraman B; Thompson PA; Blaney SM; Bernstein M; Bond M; Champagne M; Fossler MJ; Barrett JS
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):229-38. PubMed ID: 18398615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect site modelling and its application in TCI.
    Mortier E; Struys M
    Acta Anaesthesiol Belg; 2000; 51(2):149-52. PubMed ID: 11000911
    [No Abstract]   [Full Text] [Related]  

  • 18. A PC-based graphical simulator for physiological pharmacokinetic models.
    Wada DR; Stanski DR; Ebling WF
    Comput Methods Programs Biomed; 1995 Apr; 46(3):245-55. PubMed ID: 7656558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of human oral pharmacokinetics using nonclinical data: examples involving four proprietary compounds.
    Fura A; Vyas V; Humphreys W; Chimalokonda A; Rodrigues D
    Biopharm Drug Dispos; 2008 Nov; 29(8):455-68. PubMed ID: 18989850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetics of levetiracetam and dosing recommendation in children with epilepsy.
    Chhun S; Jullien V; Rey E; Dulac O; Chiron C; Pons G
    Epilepsia; 2009 May; 50(5):1150-7. PubMed ID: 19175400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.